Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shadding in prostate cancer

Jennifer D. Wu*, Lily M. Higgins, Alexander Steinle, David Cosman, Kathy Haugk, Stephen R. Plymate

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

259 Scopus citations

Abstract

The MHC class I chain-related molecules (MICs) have previously been shown to be induced on most epithelial tumor cells. Engagement of MIC by the activating immune receptor NKG2D triggers NK cells and augments antigen-specific CTL anti-tumor immunity. The MIC-NKG2D system was proposed to participate in epithelial tumor immune surveillance. Paradoxically, studies suggest that tumors may evade MIC-NKG2D-mediated immunity by MIC shedding-induced impairment of effector cell function. Here we demonstrate the first evidence to our knowledge of a significant correlation of MIC shedding and deficiency in NK cell function with the grade of disease in prostate cancer. MIC is widely expressed in prostate carcinoma. The presence of surface target MIC, however, is counteracted by shedding. A significant increase in serum levels of soluble MIC (sMIC) and deficiency in NK cell function was shown in patients with advanced cancer. Finally, the deficiency in NK cell function can be overcome by treatment with IL-2 or IL-15 in vitro. Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.

Original languageEnglish (US)
Pages (from-to)560-568
Number of pages9
JournalJournal of Clinical Investigation
Volume114
Issue number4
DOIs
StatePublished - Aug 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shadding in prostate cancer'. Together they form a unique fingerprint.

Cite this